Overview

• A Phase I trial involving 48 healthy volunteers and 25 people with type 2 diabetes found the oral treatment to be well-tolerated with no loss of muscle mass.
• The pill works as a β2 agonist that activates metabolic pathways in skeletal muscle rather than suppressing appetite.
• Preclinical studies in rodents demonstrated improved blood sugar control and body composition without gastrointestinal side effects or heart overstimulation.
• Researchers say the drug can function both as a standalone therapy and alongside GLP-1 agonists due to its complementary mechanism of action.
• Biotech firm Atrogi AB plans a larger Phase II study in patients with type 2 diabetes and obesity to assess its efficacy on weight, muscle preservation, and glycemic outcomes.